Sarissa Capital Management LP
CIK
1577524
Location
GREENWICH, CT
Portfolio Value
Small
$157,636,953
Diversification
Moderately concentrated
Filing Date
Global Rank
#4,716
/ 8,603
▼ 647
· as of Mar 2026
Top Industry
Biotechnology
46.4%
3Y Alpha vs SPY
-18.7%
Period ended 3 months ago
Filed May 15, 2026 · 55d
25 quarters · since Mar 2020
Clone Performance
Jul 2023–Jul 2026 · vs SPYHypothetical growth of cloning every reported 13F position and rebalancing on each filing, indexed to the same start.
Cloned portfolio
+6.8%
SPY
+76.5%
Annualised alpha
-18.6%
Max drawdown
−48.3%
Estimate. 13F holdings are quarter-lagged and long-only, so the clone rebalances about 45 days after each period end — when the filing becomes public — and excludes options and short positions. Past performance does not predict future results.
Portfolio Concentration
9 positions · as of Mar 31, 2026 · Δ vs Dec 31, 2025Top Position
31.5%
+6.2 pts
Top 5
86.6%
−3.8 pts
Top 10
100.0%
0.0 pts
HHI
1,910
Moderately concentrated+46
Portfolio Trend
25 quarters · across all stocks
Sector Breakdown
As of Mar 31, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $157,636,953 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
1 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| BHVN | Biohaven Ltd. | +50,000 | 563,184 | $4,764,536 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced
5 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| IRWD | Ironwood Pharmaceuticals Inc | −6,730,800 | 9,188,635 | $32,252,108 | |
| INVA | Innoviva, Inc. | −685,072 | 2,130,950 | $49,651,135 | |
| NBIX | Neurocrine Biosciences Inc | −186,618 | 116,533 | $15,352,057 | |
| CYTK | Cytokinetics Inc | −167,734 | 228,623 | $15,068,541 | |
| LNTH | Lantheus Holdings, Inc. | −14,531 | 166,919 | $12,660,806 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarterNo qualifying positions this quarter.
Sold Out
Positions the filer fully exitedNo qualifying positions this quarter.
9 positions ·
$157,636,953 total
· as of Mar 31, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| INVA |
Innoviva, Inc.
Healthcare
|
Reduced | 2,130,950 | $49,651,135 | 31.50% | |
| IRWD |
Ironwood Pharmaceuticals Inc
Healthcare
|
Reduced | 9,188,635 | $32,252,108 | 20.46% | |
| AMRN |
Amarin Corp Plc\Uk
Healthcare
|
Held | 1,673,395 | $24,197,291 | 15.35% | |
| NBIX |
Neurocrine Biosciences Inc
Healthcare
|
Reduced | 116,533 | $15,352,057 | 9.74% | |
| CYTK |
Cytokinetics Inc
Healthcare
|
Reduced | 228,623 | $15,068,541 | 9.56% | |
| LNTH |
Lantheus Holdings, Inc.
Healthcare
|
Reduced | 166,919 | $12,660,806 | 8.03% | |
| BHVN |
Biohaven Ltd.
Healthcare
|
Added | 563,184 | $4,764,536 | 3.02% | |
| REGN |
Regeneron Pharmaceuticals, Inc.
Healthcare
|
Held | 4,190 | $3,237,361 | 2.05% | |
| VOR |
Vor Biopharma Inc.
Healthcare
|
Held | 25,399 | $453,118 | 0.29% |